Alivus Life Sciences Limited (BOM:543322)

Market Cap	126.65B
Revenue (ttm)	22.74B
Net Income (ttm)	4.42B
Shares Out	n/a
EPS (ttm)	35.93
PE Ratio	28.67
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,193
Average Volume	4,138
Open	995.05
Previous Close	1,000.00
Day's Range	985.25 - 1,003.95
52-Week Range	743.60 - 1,335.00
Beta	n/a
RSI	50.87
Earnings Date	Apr 24, 2025

About Alivus Life Sciences

Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company’s APIs are used in various therapeutic segments, in...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 2011
• Employees: 2,014
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543322

Financial Performance

In 2023, Alivus Life Sciences's revenue was 22.83 billion, an increase of 5.64% compared to the previous year's 21.61 billion. Earnings were 4.71 billion, an increase of 0.84%.